Outlook Therapeutics, Inc.
ONS-5010
wet AMD
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ONS-5010 for wet AMD around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Federal Dispute Resolution meeting with the Office of New Drugs at the U.S. Food and Drug Administration (FDA) to appeal the complete response letter (CRL) dated December 30, 2025”